Precision medicine

Melissa Hurst Practice Leader for Healthcare at Slone Partners

Retrieved on: 
Thursday, August 18, 2022 - 9:00am
People, Mentorship, Precision medicine, College, Professional development, Special, Hospital, University, Bachelor of Arts in Organizational Psychology, Doctor of Philosophy, Graduate, Health, Biotechnology, Executive search, Recruitment, Korn Ferry, Hurst, Consultant, Health care, Management

SOUTH RIDING, Va., Aug. 18, 2022 /PRNewswire-PRWeb/ -- Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, has announced that Melissa Hurst has been named Practice Leader for Healthcare. With her extensive background in healthcare executive search, Hurst will focus on expanding the company's client base with hospitals, health systems, and academic centers. She will also retain her current title of Vice President of Executive Search in which she owns and leads executive level searches with a direct team of consultants whom she manages and mentors.

Key Points: 
  • SOUTH RIDING, Va., Aug. 18, 2022 /PRNewswire-PRWeb/ -- Slone Partners , a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, has announced that Melissa Hurst has been named Practice Leader for Healthcare.
  • "Melissa Hurst is a very smart, talented, and experienced leader in healthcare executive search," said Slone Partners CEO Leslie Loveless .
  • "As Practice Leader, she will drive our strategic efforts to build out Slone Partners' healthcare client base and expand our partnerships with some of the most innovative and high-performing hospitals and health systems in the country."
  • Slone Partners delivers the leaders who build amazing and diverse life sciences and healthcare organizations People Are Our Science.

Exscientia Business Update for Second Quarter and First Half 2022

Retrieved on: 
Wednesday, August 17, 2022 - 9:01pm
Software, Research, General Health, Pharmaceutical, Oncology, Medical Devices, Technology, Health Technology, Clinical Trials, Science, Biotechnology, Health, Multimedia, Precision medicine, Table, Drug discovery, Inflammation, Surface plasmon resonance, BID, UK Research and Innovation, Trust law, Technology, USD, Toxicity, IND, Achievement, MAD, Research, GBP, DevOps, Probability, BMS, British Empire Medal, GPCR, Wellcome Trust, SAD, ACS Medicinal Chemistry Letters, Company, International, CTA, Federal Reserve Bank, Innovation, Partnership, MBE, Economics, Â, Biology, BST, Cheminformatics, Most, Journal, ID, Immunity, Federal Reserve Bank of New York, Journal of Chemical Information and Modeling, Pharmacokinetics, Pharmaceutical industry, Cryptocurrency, Vaccine, Medical imaging, Medical device, Online gambling, Bayer, Sanofi

View the full release here: https://www.businesswire.com/news/home/20220817005681/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220817005681/en/
    Recent developments in the Companys pipeline, collaborations, and operations, as well as financial results for the second quarter and first half 2022, are summarised below.
  • In addition, Exscientia will host a conference call Thursday, August 18 at 1:30 p.m. BST / 8:30 a.m.
  • In the first half of 2022, we delivered on major new and existing collaborations, advanced our pipeline programmes, and marked the 10-year anniversary of Exscientias founding.
  • A replay will be available for 90 days under "Events and Presentations in the Investors and Media section of the Exscientia website .

Preparing for Continuing Battle with COVID, MicroGEM Partners with Medline to Equip Healthcare Providers with World's First Saliva PCR Test for Point of Care

Retrieved on: 
Wednesday, August 17, 2022 - 7:10pm
FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Multimedia, Biomarker, Acceleration, Laboratory, Precision medicine, Federal Food, Drug, and Cosmetic Act, NIH, Omicron, United States Department of Health and Human Services, Disaster medicine, R, Diagnosis, EUA, BBC, COVID, Center, National Institute, Molecular biology, National, Saliva, Department, Government, Human services, Patient, CDC, COVID-19 contracts in the United Kingdom, COVID-19, Infection, Medical imaging, View, Partnership, RNA, Virus, Biological engineering, Korea Disease Control and Prevention Agency, National Institutes of Health, National Institute of Biomedical Imaging and Bioengineering, Solution, Severe acute respiratory syndrome coronavirus 2, Live, PCR, Medicine, Food, Efficiency, COVID-19 testing, Pharmaceutical industry, Medical device, MEDLINE

CHARLOTTESVILLE, Va., Aug. 17, 2022 /PRNewswire/ -- MicroGEM, a U.S.-based molecular biology company, today announced that Medline, a manufacturer and distributor of medical supplies to healthcare providers across the continuum of care, is now offering the MicroGEM Sal6830 Point of Care PCR System and SARS-CoV-2 Saliva Test.

Key Points: 
  • "Our partnership with MicroGEM expands our product portfolio to offer a saliva-based test for the first time.
  • Medline is a healthcare company; a manufacturer, distributor, and solutions provider focused on improving the overall operating performance of healthcare.
  • Partnering with healthcare systems and facilities across the continuum of care, Medline provides the clinical and supply chain resources required for long-term financial viability in delivering high-quality care.
  • Headquartered in Northfield, Ill., Medline has 30,000+ employees worldwide and does business in more than 125 countries and territories.

Nonacus Welcomes Two Senior Leadership Hires: Dr Andy Feber and Dr Samuel Clokie

Retrieved on: 
Wednesday, August 17, 2022 - 9:00am
Genomics, Machine learning, Royal Marsden Hospital, Genetic testing, Precision medicine, University of Dundee School of Medicine, NIH, CEO, Division, Cancer Research UK, Diagnosis, Technology, Cancer, Research, Bioinformatics, Oncogenomics, Institute, Patient, DNA, Translation, Associate, Doctor of Philosophy, RNA-Seq, Artificial intelligence, Workflow, University, University College London, Liquid biopsy, Development, Dietary supplement, Medical imaging, Circadian rhythm, Biochemistry

BIRMINGHAM, England, Aug. 17, 2022 /PRNewswire/ -- Nonacus Ltd, leading provider of genetic testing products for precision medicine and liquid biopsy, is very pleased to announce the appointment of two senior leadership hires: Dr Andy Feber as Clinical Directorof Research and Development and Dr Samuel Clokie as Director of Bioinformatics & Data Science.

Key Points: 
  • BIRMINGHAM, England, Aug. 17, 2022 /PRNewswire/ -- Nonacus Ltd, leading provider of genetic testing products for precision medicine and liquid biopsy, is very pleased to announce the appointment of two senior leadership hires: Dr Andy Feber as Clinical Directorof Research and Development and Dr Samuel Clokie as Director of Bioinformatics & Data Science.
  • CEO of Nonacus, Chris Sale commented, "Our technology has now been proven in the liquid biopsy translational research and clinical setting.
  • Sam's responsibilities will encompass Bioinformatics team leadership and developing bioinformatic data analysis strategies to align with Nonacus' strategic objectives.
  • Nonacus provides a complete workflow for liquid biopsy analysis with the goal of enabling better cancer care through earlier diagnosis, treatment stratification and monitoring.

Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio’s Investigational Compound Being Developed for Patients with AML

Retrieved on: 
Tuesday, August 16, 2022 - 9:05pm
FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Acute myeloid leukemia, U.S. Securities and Exchange Commission, SYK, Phase 3, Risk, NDA, Precision medicine, MRD, Forward-looking statement, GLOBE, Drug, Private Securities Litigation Reform Act, SEC, Cancer, Clinical trial, EFS, Research, Security (finance), AML, CDK9, Patient, Cell, SAN, Therapy, NPM1, Safety, PMA, Mutation, Nasdaq, LinkedIn, Cdx, New Drug Application, Food, Global health, Factor X, KRON, Medical imaging, Medical device, Pharmaceutical industry, Management, Entospletinib, Kronos

SAN MATEO, Calif. and SAN DIEGO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider of diagnostic kits and services for oncology, today announced their agreement to develop a companion diagnostic (CDx) for use with Kronos Bio’s investigational therapy, entospletinib.   Entospletinib is Kronos Bio’s lead clinical compound, currently in the ongoing Phase 3 registrational AGILITY study for the treatment of newly diagnosed NPM1-mutated acute myeloid leukemia (AML).

Key Points: 
  • Entospletinib is Kronos Bios lead clinical compound, currently in the ongoing Phase 3 registrational AGILITY study for the treatment of newly diagnosed NPM1-mutated acute myeloid leukemia (AML).
  • The diagnostic will screen for the NPM1 mutation, which is present in approximately one-third of all patients with AML.
  • The FDA requires the validation and approval of companion diagnostics used to select patients for treatment with a specific therapeutic agent.
  • The agreement builds on Invivoscribes experience in developing and obtaining approval for diagnostics used for identification of patients with genetically mutated AML.

Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML

Retrieved on: 
Tuesday, August 16, 2022 - 9:05pm
FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Acute myeloid leukemia, SYK, Risk, NDA, Precision medicine, MRD, Forward-looking statement, Drug, Private Securities Litigation Reform Act, SEC, Cancer, Clinical trial, EFS, Security (finance), Research, AML, CDK9, Patient, Cell, SAN, Therapy, NPM1, Safety, PMA, Mutation, Swiss Precision Diagnostics, Nasdaq, LinkedIn, Cdx, New Drug Application, Food, Global health, Factor X, KRON, Medical imaging, Medical device, Pharmaceutical industry, Entospletinib

SAN MATEO, Calif. and SAN DIEGO, Aug. 16, 2022 /PRNewswire/ -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider of diagnostic kits and services for oncology, today announced their agreement to develop a companion diagnostic (CDx) for use with Kronos Bio's investigational therapy, entospletinib. Entospletinib is Kronos Bio's lead clinical compound, currently in the ongoing Phase 3 registrational AGILITY study for the treatment of newly diagnosed NPM1-mutated acute myeloid leukemia (AML).

Key Points: 
  • The diagnostic will screen for the NPM1 mutation, which is present in approximately one-third of all patients with AML.
  • The FDA requires the validation and approval of companion diagnostics used to select patients for treatment with a specific therapeutic agent.
  • The agreement builds on Invivoscribe's experience in developing and obtaining approval for diagnostics used for identification of patients with genetically mutated AML.
  • "This companion diagnostic NPM1mutation assay development work with Kronos Bio represents a significant milestone for our company," said Jeffrey Miller, Ph.D., chief scientific officer and chief executive officer of Invivoscribe.

Deepcell Names Human Resources Veteran Kady Cooper as Head of People to Support Rapid Growth

Retrieved on: 
Tuesday, August 16, 2022 - 2:00pm
Technology, Research, Genetics, Software, Biotechnology, Health, Data Management, Science, Artificial Intelligence, People, Senior Professional Baseball Association, Multimedia, Professional in Human Resources, HR, Intelligence, Precision medicine, Industry, MS, CEO, SHRM, CA, Technology, Growth, San Francisco Bay Area, Forbes, Research, Engineering, Cell, Cornell University, Human resources, Eye, Cell biology, Deep learning, Analytics, Fortune 500, Bias, Head, Science, Human resource management, Solution, Inclusion, BS, Management, Medical device, Microscope, Diversity

Kady has over 20 years of Human Resources experience supporting fast-growing start-ups and Fortune 100 companies in the San Francisco Bay Area.

Key Points: 
  • Kady has over 20 years of Human Resources experience supporting fast-growing start-ups and Fortune 100 companies in the San Francisco Bay Area.
  • She earned a BS and MS in Human Resources Management and completed a certificate in Diversity and Inclusion from Cornell.
  • Im thrilled to welcome Kady Cooper to Deepcell as Head of People.
  • Deepcell has experienced rapid growth across a diverse set of departments, across commercial, research and development, and operations.

Zephyr AI Appoints Allen Hodge as Chief Commercial Officer

Retrieved on: 
Tuesday, August 16, 2022 - 1:00pm
Software, Biotechnology, Pharmaceutical, Health, Artificial Intelligence, Data Management, Health Technology, Technology, Hematology, Precision medicine, Encorafenib, Drug discovery, CEO, Senior, Algorithm, ViroPharma, Growth, Cancer, Leadership, BioCryst Pharmaceuticals, Zephyr, Research, Pfizer, Marketing, Patient, Instagram, Twitter, Sutro Biopharma, Shire (pharmaceutical company), Hodge, Array BioPharma, Red Cell, BRAF, Diabetes, Hereditary angioedema, Solution, LinkedIn, Celgene, Organization, Pharmaceutical industry, Medical device, United, Berotralstat

Zephyr AI, Inc. (Zephyr AI), a high-growth healthcare technology company committed to radically reshaping traditional approaches to drug discovery precision medicine and predictive analytics has announced the appointment of Allen Hodge as Chief Commercial Officer.

Key Points: 
  • Zephyr AI, Inc. (Zephyr AI), a high-growth healthcare technology company committed to radically reshaping traditional approaches to drug discovery precision medicine and predictive analytics has announced the appointment of Allen Hodge as Chief Commercial Officer.
  • At Zephyr AI, Hodge provides senior leadership and strategic vision to support the companys commercial efforts.
  • The Zephyr AI team is poised to transform the way that the healthcare industry approaches drug discovery, development, and predictive analytics, said Hodge, Chief Commercial Officer of Zephyr AI.
  • As we enter into our next phase of evolution and growth as a company, it is incredibly exciting to welcome Allen to the Zephyr AI team, said David L. Morgan II, CEO of Zephyr AI.

High Potency APIs Global Market Opportunities And Strategies 2022: Rise in the Number of Cancer Cases, Growing Focus on Precision Medicine and Increasing Ageing Population to Propel Future Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 16, 2022 - 11:00am
Health, General Health, Investment, Precision medicine, API, Awareness, CAGR, Plasma protein binding, Artificial intelligence, Population, Growth, Fine chemical, Pharmaceutical industry

The "High Potency APIs Global Market Opportunities And Strategies To 2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "High Potency APIs Global Market Opportunities And Strategies To 2031" report has been added to ResearchAndMarkets.com's offering.
  • The global high potency APIs market reached a value of nearly $19,772.2 million in 2021, having grown at a compound annual growth rate (CAGR) of 5.2% since 2016.
  • Going forward, a rise in the number of cancer cases, growing focus on precision medicine and increasing ageing population will drive the growth.
  • Player-adopted strategies for the high potency APIs market include focus on strategic investments to expand operations, focus on new product approvals and focus on improving production capabilities through strategic investments.

Diversity, Equity, and Inclusion Strategies by Slone Partners Receives HRCI Accreditation

Retrieved on: 
Tuesday, August 16, 2022 - 9:00am
People, Education, Strategic planning, Precision medicine, Accreditation, AP, Time, CEO, DEI, Organization, Medicine, Management

SOUTH RIDING, Va., Aug. 16, 2022 /PRNewswire-PRWeb/ -- Diversity, Equity, and Inclusion (DEI) Strategies by Slone Partners has received Approved Provider (AP) accreditation from the HR Certification Institute® (HRCI®). As an AP, DEI Strategies at Slone Partners will offer quality public continuing education events/training and private engagements that are pre-approved based on aligning with HRCI's Exam Content Outlines. The events meeting those outlines will be made available to thousands of global HRCI-certified professionals who must earn recertification credits to maintain their credentials.

Key Points: 
  • SOUTH RIDING, Va., Aug. 16, 2022 /PRNewswire-PRWeb/ -- Diversity, Equity, and Inclusion (DEI) Strategies by Slone Partners has received Approved Provider (AP) accreditation from the HR Certification Institute (HRCI) .
  • As an AP, DEI Strategies at Slone Partners will offer quality public continuing education events/training and private engagements that are pre-approved based on aligning with HRCI's Exam Content Outlines.
  • "I am excited that our DEI Strategies division has received AP accreditation from the HRCI," said Leslie Loveless , CEO of Slone Partners.
  • To learn more about Slone Partners' value proposition and processes, visit http://www.slonepartners.com or call 888.784.3422.